Reshma Kewalramani, Vertex CEO (Vertex)

A year out from FDA ap­proval, Ver­tex looks to ex­pand top-sell­ing CF drug to pe­di­atrics

About a year af­ter get­ting the FDA thumbs-up for its block­buster cys­tic fi­bro­sis drug Trikaf­ta, Ver­tex is pick­ing up where it left off.

The Boston-based biotech read out pos­i­tive re­sults from a Phase III study in­volv­ing chil­dren ages 6 to 11, and an­nounced plans to file for a sup­ple­men­tal NDA lat­er this year. Pre­vi­ous­ly, the triplet reg­i­men was on­ly avail­able to pa­tients 12 and up.

Trikaf­ta, Ver­tex’s $VRTX fourth CF drug, is de­signed for those with at least one F508del mu­ta­tion in the CFTR gene. It cov­ers about 90% of CF pa­tients, un­like the com­pa­ny’s Ka­ly­de­co, which on­ly cov­ers 6% of Amer­i­cans with CF, ac­cord­ing to a STAT re­port. With­in weeks of Trikaf­ta’s Oc­to­ber 2019 launch, it be­came Ver­tex’s top-sell­ing drug. Quar­ter­ly US sales hit $420 mil­lion by the end of Jan­u­ary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA